drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (autologous CAR-T)
drug_description
Autologous gene-modified CAR T-cell therapy for relapsed/refractory multiple myeloma; patient T cells are engineered to express a CAR that recognizes myeloma-associated antigens and, upon binding, activates T-cell cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T cells are gene-modified to express a chimeric antigen receptor that recognizes myeloma-associated surface antigens; upon antigen binding, CAR signaling activates and expands the T cells, inducing cytokine release and targeted cytotoxic killing of malignant plasma cells.
drug_name
LCAR-M61S
nct_id_drug_ref
NCT06472479